Facts about the First-HD Study

- First-HD is a study to determine if SD-809 ER (an investigational drug) is safe and effective in reducing chorea associated with Huntington disease.
- SD-809 ER is a slowly releasing form of tetrabenazine. Tetrabenazine is currently approved in the United States and Canada for the treatment of chorea.

How long is the study and what will it cost to participate?

- Participants will be involved in this trial for approximately 4 months.
- At least 8 in-person visits to the study center will be required and 7 telephone assessments will be conducted.
- Study-related examinations and study drug are provided to you at no cost.

Who can participate in First-HD?

- You may be eligible to participate if you:
  - Have been diagnosed with Huntington disease and have never taken tetrabenazine.
  - Are at least 18 years old or the age of majority in your State or Province, whichever is older.
  - Have a caregiver who can come with you to the research visits.

How can I find out more about First-HD?

www.Huntington-Study-Group.org
1-800-487-7671 (North America)
www.auspexpharma.com
www.ClinicalTrials.gov